-
Mashup Score: 7Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer | BioSpace - 4 year(s) ago
Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer – read this article along with other careers information, tips and advice on BioSpace
Source: BioSpaceCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 1
PURPOSE This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (MBC) that is either endocrine-pretreated or hormone receptor (HR)–negative. METHODS An Expert Panel conducted a targeted systematic literature review guided by a signals approach to identify new,…
Source: Journal of Clinical OncologyCategories: Latest Headlines, Oncologists1Tweet-
Chemotherapy and Targeted Therapy for Patients With HER2- Metastatic Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology #jco @ASCO_pubs @OncoAlert #bcsm @BeverlyMoy https://t.co/aRhzBtTOBL
-
-
Mashup Score: 9Sacituzumab Govitecan for Metastatic Triple‐Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities - 4 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Oncs, Latest HeadlinesTweet-
Sacituzumab Govitecan for Metastatic Triple‐Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Review with algorithms to manage common AEs @OncJournal #bcsm @MGHCancerCenter @hoperugo https://t.co/K6dmeaHSHf
-
-
Mashup Score: 10
PURPOSE Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support the use of platinum agents in the TNBC basal subtype. The EA1131 trial hypothesized that invasive disease-free survival (iDFS) would not be inferior…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @awolff: #EA1131 data just presented @ #ASCO21 & published today https://t.co/aMC6C6HA3t. The first study powered for survival as primar…
-
-
Mashup Score: 22TweetDeck - 4 year(s) ago
TweetDeck is your personal browser for staying in touch with what’s happening now.
Source: tweetdeck.twitter.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @tmprowell: If you are overwhelmed by #ASCO21 tweets, take 2 minutes & set up https://t.co/uRyXSGboaN. You choose columns: your tweets (…
-
-
Mashup Score: 9Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC - 4 year(s) ago
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent (adjuvant) treatment after surgery….
Source: www.streetinsider.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Phase 3 KEYNOTE-522 trial with pembrolizumab and chemotherapy met dual primary endpoint of higher pCR and event free survival for patients with localized high-risk TNBC. Full data to be presented at upcoming meeting. #bcsm @OncoAlert https://t.co/4kw1AcdMUY
-
-
Mashup Score: 0Remember Your Why: An Oncologist's Reflections on Running During the COVID‐19 Pandemic - 4 year(s) ago
An oncologist reflects on purpose, gratitude, and resilience during this time of uncertainty, considering changes brought about by the COVID‐19 pandemic.
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet-
Remember Your Why: An Oncologist's Reflections on Running During the COVID‐19 Pandemic. Beautiful piece by @DrAmyComander @MGHCancerCenter on purpose, gratitude, and resilience during time of uncertainty and chaos. #theoncologist #bcsm https://t.co/Q41pA5ZWaO
-
-
Mashup Score: 0Adjuvant Olaparib Showcases iDFS Improvement in BRCA+, High-Risk Early Breast Cancer - 4 year(s) ago
February 17, 2021 – An independent data monitoring committee has concluded that the phase 3 OlympiA trial examining olaparib crossed the superiority boundary for its primary end point of invasive disease-free survival in patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
Adjuvant Olaparib Associated with improved invasive disease-free survival for pts with gBRCA+, High-Risk Early Breast Cancer in Olympia trial, as per IDMC. Await release of full data. #bcsm @OncoAlert @OncLive https://t.co/jCYBison7W
-
-
Mashup Score: 1
Plasma-based genotyping identified high rates of actionable mutations, which was associated with significant application of matched therapy and better OS in patients with MBC.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Routine plasma-based genotyping for selection of matched therapy associated with improved overall survival in #metastaticbreastcancer #bcsm @MGHCancerCenter #oncoalert @CCR_AACR https://t.co/cCwdm6zlV9
-
-
Mashup Score: 4Understanding Academic Medical Centers: Simone’s Maxims - 4 year(s) ago
Academic medical centers today represent a unique fusion of traditional academia, hospital functions, several levels of education, and, above all, patients. They are complex organizations trying to discharge an often conflicting melange of responsibilities. This complexity has grown in recent years
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @GeneCollector: A must read. Understanding Academic Medical Centers: Simone’s Maxims https://t.co/tGpXOQSVye
-
Withdrawal of Atezolizumab (Tecentriq) Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer. Will impact choice of immunotherapy and PD-L1 testing for pts with mTNBC. #bcsm @OncoAlert https://t.co/kPSAAtziGG